-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VK-2809 in Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2809 in Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2809 in Fibrosis Drug Details: VK-2809 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VK-0612 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-0612 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-0612 in Type 2 Diabetes Drug Details: VK-0612 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VK-2809 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: VK-2809 is...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...